Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: etanercept

Tofacitinib Effective for Treating Moderate-to-Severe Chronic Plaque Psoriasis

Reuters Staff  |  

NEW YORK (Reuters Health)—Tofacitinib is better than placebo (and noninferior to etanercept) for treating patients with moderate-to-severe chronic plaque psoriasis, according to Pfizer’s OPT Compare trial. In an earlier 12-week, phase 2b, dose-ranging trial, the oral JAK inhibitor tofacitinib proved to be more effective than placebo for treating patients with moderate-to-severe plaque psoriasis. Based on…

Biologic Drugs for Psoriasis Are Rarely Stopped for AEs

Joan Raymond  |  

NEW YORK (Reuters Health)—Real-world psoriasis patients receiving biologic therapies rarely stop taking the drugs because of adverse effects, researchers say. Although data from long-term registries have shown similar results, “the demographics of patients in registries are somewhat different than those of patients in real-world practices,” Dr. Jensen Yeung told Reuters Health by email. “I have…

Anti-TNF Agents May Improve Clinical Symptoms of Ankylosing Spondylitis

  |  

Ankylosing spondylitis primarily affects the joints and ligaments of the spine, but may also have an impact on other joints. Patients experience pain and stiffness that limit mobility in the back and other affected joints. Symptoms can come and go, last for long periods of time and be severe. Anti-tumor necrosis factor (anti-TNF) drugs are…

Case Report: Rheumatoid Arthritis and Degenerative Disk Disease

Patricia Frisch, PhD; Ronald R. Butendieck, MD; Andy Abril, MD; Peter M. McIntosh, MD; Salim M. Ghazi, MD; Elliot L. Dimberg, MD; Lynn F. Feldman, DO; David G. Lucas, MD; and Andrea Styron, MSR-PT  |  

Combination therapy includes abatacept for patient with erosive, chronic RA, underlying osteoarthritis and degenerative disk disease